Latest Industry Insights

Technology Networks spoke with Michael Yang, president and chief executive officer of ViaCyte, to learn more about the development of a stem cell-derived therapy for the treatment of T1D and the technology behind it.

As we seek a better tomorrow, here are three predictions from global life science and diagnostics company, PerkinElmer, that will lead to better health outcomes.

How do we continue to push the boundaries in analytical capabilities, increase confidence in results and apply MS to a wider range of research questions? Technology Networks posed these questions to Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, in a recent interview.

Technology Networks spoke with Jonathan Hare, PhD, Imophoron’s Head of Immunology, to learn more about the ADDomer™ vaccine platform, the benefits of administering vaccines by a variety of administrative routes and the infectious diseases they are currently working to develop vaccines for.

Dr. Arvind Varsani discusses the work that the global scientific community has achieved through collaboration, especially in the pandemic.

In this article, we discuss the use of autoantibodies to diagnose and monitor type 1 diabetes mellitus and provide some future perspectives on potential therapies beyond insulin.

Certara is developing biosimulation and tech-enabled approaches to help scientists answer key questions at various stages of the development pipeline, serving to inform and accelerate the path to regulatory approval. One such approach, the company’s Vaccine Simulator™, can be leveraged across different therapeutic areas to determine optimal vaccine dosing and dosing regimens for different patient cohorts.

Technology Networks spoke with Dr. Bertram Brenig and Illumina to find out more about how studying genetic differences in honey bees will improve breeding programs, and how Illumina will support this research.

In this interview, Dr. Huang discusses the advantages of the direct PCR approach and explains why uptake has so far not been greater.

Clinicians have been using AMH in treatments related to reproductive health for over 20 years. High-quality diagnostic assays have come on in leaps and bounds over that time, continuing to provide precise insights to support clinical decisions made in the areas of reproductive aging, fertility and pregnancy monitoring.